Augustine Therapeutics

NEWS ALERT! 📢 We are excited to announce the completion of a €17 million ($18.5 million) Series A first close to advance our differentiated HDAC6 inhibitor pipeline to the clinic and support expansion of our R&D and management team. This funding round is led by Asabys Partners, with the participation of Eli Lilly and Company and the US CMT Research Foundation, alongside continued support from our historical investors PMV, AdBio partners, V-Bio Ventures, VIB and GEMMA FRISIUS - FONDS K.U.LEUVEN. As part of this milestone, we welcome Clara Campàs Moya, Managing Partner and co-founder of Asabys Partners, to the Augustine Board of Director, and announce the appointment of Gerhard Koenig as executive Chairman. Stay tuned 🔊 for further updates as we prepare to transition into the clinic with our lead program! To learn more, read the full press release here: https://lnkd.in/eVtvQUdv #AugustineTx #SeriesA #CMT

Augustine Therapeutics will be participating in the 2024 Peripheral Nerve Society (PNS) Annual Meeting at the Palais des Congrès de Montréal, Canada, on 22-25 June 2024. The event is the largest international research conference across specialties in peripheral neuropathy. It is a great opportunity to connect with globally acknowledged researchers, clinicians, and investigators in the field. Our Head of Early Clinical Development, Cedric Szyndralewiez, MSc. will be attending the 3-day conference and be available for 1-1 meetings to share our progress towards a new therapeutic approach selectively targeting HDAC6 inhibition for the potential treatment of inherited and hereditary neuropathies such as Chemotherapy-Induced Neuropathy and Charcot-Marie-Tooth disease. For more information on the event: https://lnkd.in/geae8FDb #PNS2024 #cmt #biotech #RandD #HDAC6

Augustine Therapeutics will be participating in the 3rd ALS Drug Development Summit on May 21-23, 2024 in Boston, MA. This summit gathers executives and scientific experts from international pharmaceutical companies across discovery, preclinical, clinical, regulatory, and commercial disciplines to help shape the future of ALS drug development. Our Head of Pharmacology, Dr. Jonathan van Eyll will be attending the 2-day conference and be available for 1-1 meetings to share our progress towards a new therapeutic approach selectively targeting HDAC6 inhibition for the potential treatment of ALS. In February 2024, we announced a collaboration with The ALS Association through the Lawrence and Isabel Barnett Drug Development Program, aiming at profiling our novel HDAC6 lead candidates in efficacy and safety studies. HDAC6 is a promising and innovative therapeutic target for the treatment of ALS, originating from the groundbreaking research of our scientific founder Professor Ludo Van Den Bosch at the VIB-KU Leuven Center For Brain & Disease Research, in closed collaboration with Professor Philip Van Damme from the University Hospital in Leuven and the Leuven Center for ALS (LEUCALS). For more information on the event: https://lnkd.in/dniXwpiR #ALS #HDAC6 #TDP43 #Biotech #R&D #ALSDrugDiscovery  

Augustine Therapeutics will be participating in the 24th #BioEquityEurope on May 12-14, 2024 in San Sebastián, Spain, as well as during May 21-22 virtual partnering days. Our CEO, Dr. Sylvain Celanire, and Chairman, Dr. Gerhard Koenig will be available for one-on-one meetings throughout the conference, to share the progress of our unique assets targeting HDAC6 inhibition for the potential treatment of PNS, CNS and cardio-metabolism diseases. Please reach out through the conference online partnering system. Look for more information: Bio€quity Europe 2024 (biocentury.com) BioCentury Inc. #biotech #innovation #CMT #CIPN #ALS #biopharma

Augustine Therapeutics announces collaboration with The ALS Association through the Lawrence and Isabel Barnett Drug Development Program to advance novel brain penetrant and selective HDAC6 inhibitors as an emerging and potential treatment of ALS. Read the full announcement here: https://lnkd.in/d6nsi4NB #ALS #innovation #HDAC6 #therapeutics

The Augustine Therapeutics team wish you a Merry Christmas and a healthy and successful 2024 !!

Augustine Therapeutics will be participating to the BIO-EUROPE conference in Munich, Germany on 6-8 November 2023. Sylvain Celanire, CEO will be available for one-on-one meetings throughout the 3-day conference. To schedule a meeting, please reach out to us via: https://lnkd.in/gRkjn8M We will be sharing the latest development on our small molecule HDAC6 inhibitor projects portfolio, including our peripheral-restricted clinical candidate AGT100216 advancing into regulatory development for Charcot-Marie-Tooth disease and Chemotherapy-induced neuropathies, as well as our brain penetrant selective HDAC6 inhibitor program for neurodegenerative diseases, including ALS. ➡ Agenda of Bio-Europe: https://lnkd.in/eXzpc2S2 #lifesciences #bioeurope #biopharma #CIPN  #CMT #ALS #innovation

Catch up with Sylvain Celanire, CEO and Marie Trad, CMO at the Global CMT Research Convention happening on Sept 22nd -23rd 2023 in Boston!

Meet our new members at Augustine Therapeutics! We are pleased to announce new appointments to our Leadership team to support the preclinical and clinical development of our peripheral-restricted and centrally acting selective HDAC6 inhibitor pipeline! Marie Trad joins us as our Chief Medical Officer with extensive experience in clinical and pharmaceutical development in the field of neurology, neuromuscular, and neuropathies, leading global clinical development from early stages throughout the lifecycle of Augustine’s assets development. Jonathan van Eyll joins as our Head of Pharmacology. His large experience spanning from in vitro and in vivo translational pharmacology to clinical disease biomarkers of neuroscience therapeutics will strengthen our expertise in accelerating the discovery and development of selective HDAC6 inhibitors for neuromuscular and neurological diseases. Finally, Cedric Szyndralewiez joins us as Head of Non-Clinical and Early Development, with a strong track record in leading and advancing multiple drug candidates through all stages of preclinical, IND approval to First-in-Patient studies. We are also expanding our discovery and development platform by joining the Leuven-based Arenberg Accelerator, accessing state-of-the-art laboratories and offices! Exciting times for Augustine Therapeutics thanks to the continuous support of our historical investors V-Bio Ventures, PMV, AdBio partners, #VIBNewVentures, VIB, and GEMMA FRISIUS - FONDS K.U.LEUVEN! To learn more about our exciting new team members, read the full Press Release here: https://lnkd.in/eabJnxNM #newappointment #biotech #team #healthcare #innovation #pharma #drugdevelopment

Augustine Tx is still hiring! Share this exciting profile within and beyond your network and apply today! #pharmacology #biotechjobs #invitro #cmt #jobalerts